Opening book details…
Can I read Baricitinib for the treatment of refractory vascular Behçet's disease on EtoBox?
Baricitinib for the treatment of refractory vascular Behçet's disease by Zhimian Wang; Xiaoou Wang; Weiwei Liu; Yuhua Wang; Jinjing Liu; Li Zhang; Shangzhu Zhang; Xinping Tian; Yan Zhao; Wenjie Zheng is a Immunology and Microbiology article available to read on EtoBox.
What is Baricitinib for the treatment of refractory vascular Behçet's disease about?
Objective The pilot study aims to evaluate the effectiveness and safety of baricitinib in Behcet's Disease (BD) patients with refractory vascular involvement. Methods We consecutively enrolled vascular/cardiac BD patients who received baricitinib (2 mg/day) along with glucocorticoids (GCs) and immunosuppressants in our center. Efficacy assessment mainly depends on the proportion of clinical remission and side effects were recorded. Results 17 patients (12 males) were included with a mean follow-up of 10.7 ± 5.3 months. At 3 months of follow-up, 76.5% of patients achieved a complete response and the proportion increased to 88.2% at the last visit. During follow-up, ESR (p < 0.01) and hsCRP (p < 0.0001) decreased significantly, as well as Behçet's Disease Current Activity Form score (p < 0.01). In addition, baricitinib showed a GCs-sparing effect. No serious adverse events were noted. Conclusions Our study suggests that baricitinib is well-tolerated and effective in treating refractory vascular/cardiac BD patients.
Who reads Baricitinib for the treatment of refractory vascular Behçet's disease?
It is typically read by researchers, students, and practitioners in Immunology and Microbiology.
- Author
- Zhimian Wang; Xiaoou Wang; Weiwei Liu; Yuhua Wang; Jinjing Liu; Li Zhang; Shangzhu Zhang; Xinping Tian; Yan Zhao; Wenjie Zheng
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Immunology and Microbiology (Life Sciences)